Free Trial

BioSyent (CVE:RX) Stock Price Crosses Below 50-Day Moving Average - What's Next?

BioSyent logo with Medical background

BioSyent Inc. (CVE:RX - Get Free Report)'s share price crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of C$11.66 and traded as low as C$11.41. BioSyent shares last traded at C$11.41, with a volume of 6,100 shares trading hands.

BioSyent Trading Up 0.4%

The business has a fifty day moving average of C$11.68 and a 200-day moving average of C$11.17. The company has a debt-to-equity ratio of 2.90, a quick ratio of 6.91 and a current ratio of 3.92. The company has a market capitalization of C$130.96 million, a P/E ratio of 18.58 and a beta of 0.93.

About BioSyent

(Get Free Report)

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.

Read More

Should You Invest $1,000 in BioSyent Right Now?

Before you consider BioSyent, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioSyent wasn't on the list.

While BioSyent currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk
3 Overlooked AI Stocks That Chipmakers Can’t Live Without

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines